Monte Rosa Therapeutics Bolsa (NASDAQ: GLUE)

Últimas noticias sobre Monte Rosa Therapeutics (NASDAQ:GLUE) Bolsa

Monte Rosa Therapeutics

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics Inc

Topline results also show investigational&nbsp;targeted oral peptide&nbsp;icotrokinra&nbsp;achieved clinical remission rates up to 30.2% at Week 12 and a favorable safety profile in Phase 2b ANTHEM-UC study
Clinical response and remission rates continued to improve through Week 28, building on strong data recently reported for the plaque psoriasis Phase 3 program
Icotrokinra demonstrates potential to offer therapeutic benefit and tolerability with a once daily oral treatment
SPRING HOUSE, Pa., March 10, 2025 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:&nbsp;JNJ)&nbsp;today announced positive topline results from ANTHEM-UC, a Phase 2b study of icotrokinra (JNJ-2113), the first investigational targeted oral peptide that selectively blocks the IL-23 receptor, in adults with moderately to severely active ulcerative colitis (UC). The study met its primary endpoint of clinical responsea in all icotrokinra dose groups evaluated and demonstrated clinically meaningful differences versus placebo in key secondary endpoints of clinical remissionb, symptomatic remission and endoscopic improvement at Week 12.&nbsp;
In the ANTHEM-UC study (n=252), three doses of once daily icotrokinra were tested with all meeting the primary endpoint of clinical response at Week 12. A response rate of 63.5% for patients treated with the highest dose of icotrokinra was achieved at Week 12 versus 27% for placebo (p&lt;0.001). Further, 30.2% of patients treated with the highest dose of icotrokinra demonstrated clinical remission at Week 12 versus 11.1% of patients who received placebo (p&lt;0.001). Remission and response rates continued to improve through Week 28.1
Icotrokinra was well tolerated with proportions of participants reporting one or more adverse events (AEs) being similar between the icotrokinra dose groups and the placebo group.1

Biotech

News

General

Johnson & Johnson Announces Icotrokinra Meets Primary Endpoint Of Clinical Response In Ulcerative Colitis Study And Shows Potential To Transform The Treatment Paradigm For Patients

Chardan Capital analyst Daniil Gataulin maintains Unity Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>) with a Buy and maintains $6 price target.

Price Target

Analyst Ratings

Chardan Capital Maintains Buy on Unity Biotechnology, Maintains $6 Price Target

Baird Medical Investment Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDMD#NASDAQ">BDMD</a>) ("Baird Medical" or the "Company"), a forward-thinking medical device company specializing in AI-powered surgical robotics and next-generation surgical instruments, and a global leader in microwave ablation (MWA) technology,&nbsp;has received regulatory approval from the Indonesian Ministry of Health (Kementerian Kesehatan Republik Indonesia). This approval includes the Great Wall Microwave Therapeutic Instrument and the Great Wall Disposable Microwave Ablation Needle, laying the foundation for Baird Medical to introduce its advanced minimally invasive treatment solutions across Indonesia.

Global

BDMD

Baird Medical Secures Indonesian Regulatory Approval For Microwave Ablation Technology

Recently, the World Bank estimated that there were 1.4 billion unbanked and many more underbanked people globally. The <a href="https://www.weforum.org/stories/2024/07/why-financial-inclusion-is-the-key-to-a-thriving-digital-economy/#:~:text=The%20World%20Bank%20estimates%20that,in%20the%20global%20financial%20landscape.">lack of access to financial services</a> is a significant burden for underserved populations, making it harder to get loans and bridge financial gaps, which hurts personal finances and makes it harder to escape poverty.
Lack of access to capital in markets in areas such as Africa, most of Eastern Europe and some parts of Latin America, the Middle East, Russia and Southeast Asia also makes it harder for businesses in these markets to grow. According to the United Nations, &#8220;micro, small and medium enterprises (MSMEs) account for 90% of businesses, more than 70% of employment and 50% of GDP worldwide.&#8221;
Alex Vert, <a href="https://www.linkedin.com/in/alex-vert-fintech/">founder of LendSwap</a>, says web-based solutions incorporating Artificial Intelligence (AI) can help break the cycle of deprivation, bring more people into the global financial system, and ultimately help individual businesses grow in a way that better positions growth.
&#8220;Traditional banks often find it unprofitable to offer certain services, such as microloans, or they face regulatory restrictions that prevent them from doing so. LendSwap fills this void by providing access to financial services that would otherwise be unavailable,&#8221; Vert said.
Emerging economies like Vietnam, Mexico, Nigeria and India hold significant potential but remain underserved by traditional financial systems. According to the World Bank, over 65% of individuals and small businesses in these regions face financing constraints due to collateral requirements, slow approval processes, high interest rates, and unsustainable repayment terms.
Decentralized digital currencies, most prominently Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), tend to gain popularity during global economic and political uncertainty as institutional and retail consumers look for a safe haven, independent of the state where they can store value. Vert sees the world as ready for decentralized financing, even in emerging markets, as the Web2 world evolves into Web3.
&#8220;We see this shift toward a decentralized, AI-powered financial system as overwhelmingly positive. An open liquidity market will unlock millions of new users for Web3, reduce fees, improve transparency, and make blockchain-based finance an integral part of everyday life through continuous innovation and new financial tools.&#8221;
LendSwap uses AI to streamline the loan application, approval and disbursement processes. AI-driven risk assessment models make quick approvals without the need for human intervention. Approved loans, in turn, trigger the instant release of funds.
&#8220;We firmly believe that the future of financial services will be centered around Web3. While traditional banks and NBFIs already use AI, these institutions remain opaque, charge high fees, and are burdened with bureaucratic inefficiencies and liquidity costs. Web3 eliminates many of these issues, making it the logical evolution of the industry,&#8221; Vert says.
LendSwap says it serves over 11 million customers with a projected goal of reaching 100 million users in the next two years, with the majority of growth in India and Nigeria.
While large tech markets like the U.S. can focus on more specialized use cases like GameFi and memecoins, which address a need for speculation and entertainment, emerging markets have the most substantial need for blockchain services to fill the gaps in traditional financial services.
Liquidity and payments may not be the most disruptive use cases in concept. Still, they are the global use cases most likely to improve users&#8217; lives. A borderless, inclusive financial ecosystem is better for everyone and will ultimately help drive economic progress in markets everywhere.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Emerging Markets

Economics

Exclusives

Interview

$BTC

LendSwap Founder Says AI Tech Can Fill Lending Gaps In Emerging Markets

$911,519 grant awarded for cutting-edge equipment for the recycling of rare earth magnets and battery materials
Indiana's Recycling Market Development Program awards grants to innovative projects in the recycling sector
Electrified Materials Corporation will expand its preprocessing of end-of-life rare earth magnets, lithium-ion batteries and ferrous metals, ensuring a sustainable domestic supply chain for copper, aluminum, steel, plastic and critical minerals
FISHERS, IN / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / March 10, 2025 / American Resources Corporation's <a href="https://pr.report/8464">(NASDAQ:</a><a href="https://www.benzinga.com/stock/AREC#NASDAQ">AREC</a>) ("American Resources") announced that its wholly-owned subsidiary, Electrified Materials Corp ("Electrified Materials" or "EMCO"), has been awarded a $911,519 matching grant under the Indiana Department of Environmental Management's Waste Diversion Project. This initiative aims benefit Indiana's economy by expanding recycling infrastructure for recycling, creating jobs, and addressing supply chain challenges.
Electrified Materials is a cutting-edge recycler of metals to the electrified economy specializing in processing used metals and minerals to be recycled and further refined into new steel-based, battery-grade and magnet-grade products. Today, EMCO operates within the U.S. with its origins in reclaiming former thermal coal mines and industrial sites. By leveraging its regional logistics and infrastructure, along with its affiliation with ReElement Technologies Corporation ("ReElement"), a leader in critical minerals refining, EMCO aims to expand its footprint in the high-growth markets of used steel, rare-earth elements and critical battery materials. Additionally, EMCO remains committed to cleaning up old infrastructure left behind from the declining mining industry. Through its affiliation and collaboration with ReElement, EMCO will preprocess end-of-life waste containing critical minerals, such as wind turbines, EV motors, lithium-ion batteries, consumer power tools and e-waste, before supplying these concentrates to ReElement for further refinement into manufacturing-grade final products, ready to reenter the supply chain.

Contracts

AREC

American Resources Corp's Electrified Materials Has Been Awarded A $911,519 Matching Grant Under The Indiana Department Of Environmental Management's Waste Diversion Project

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said Fiserv, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) is &#8220;one of the <a href="https://www.benzinga.com/quote/FI">greatest fintechs.&#8221;</a>
As per recent news, Fiserv announced on March 3 that it had completed its acquisition of Payfare Inc.
When asked about Farmland Partners Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FPI#NYSE">FPI</a>), he said, &#8220;I kind of like the idea as a spec.&#8221;
On the earnings front, Farmland Partners, on Feb. 19, reported better-than-expected fourth-quarter financial results and issued FY25 FFO guidance above estimates.
Sempra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>) reported a &#8220;bad&#8221; quarter, Cramer said, &#8220;There are several things that are definite misses. It does deserve to trade lower.&#8221;
On Feb. 25, Sempra posted fourth-quarter adjusted earnings of $1.50 per share, missing market estimates of $1.60 per share. The company's sales came in at $3.76 billion, falling short of expectations of $4.36 billion.
When asked about Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), he said, &#8220;We're going to have to hold off.&#8221;
On Feb. 28, Recursion Pharmaceuticals posted worse-than-expected fourth-quarter financial results.
Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) is a &#8220;meme&#8221; stock,&#8221; the Mad Money host said. &#8220;It is not trading on the fundamentals.&#8221;
As per the recent earnings report, Rigetti Computing, on March 5, reported fourth-quarter revenue of $2.3 million, missing a Street consensus estimate of $2.5 million according to data from Benzinga Pro.
Cramer recommended to own ONEOK, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>). &#8220;I think ONEOK may be the best-run pipeline company in the country,&#8221; he added.
Supporting his view, ONEOK, on Feb. 24, posted better-than-expected quarterly earnings.
&#8220;There are still remedies that are needed. Until all the remedies happen, I am not going to approve it,&#8221; Cramer said when asked about Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>).
On March 3, JPMorgan maintained an Underweight rating on the stock, saying its filling revealed material weaknesses.
Price Action:
<ul>
<li>Fiserv shares fell 0.9% to settle at $218.04 on Friday.</li>
<li>Sempra shares slipped 0.5% to close at $69.30 during the session.</li>
<li>Rigetti Computing shares jumped 9.9% to settle at $9.35.</li>
<li>Recursion Pharmaceuticals shares climbed 5.6% to close at $6.59 on Friday.</li>
<li>ONEOK shares fell 0.2% to settle at $89.57.</li>
<li>Farmland Partners shares gained 0.5% to close at $11.15.</li>
<li>Super Micro Computer shares gained 3.2% to close at $38.24 on Friday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/03/44187903/top-2-consumer-stocks-that-could-blast-off-this-quarter">Top 2 Consumer Stocks That Could Blast Off This Quarter</a></li>
</ul>
Image: Shutterstock

Markets

Media

Trading Ideas

First Trust Advantage Preferred Income Fund

RGTI

RXRX

SMCI

Jim Cramer: Fiserv Is 'One Of The Greatest Fintechs,' Calls This Tech Company A Meme Stock

B of A Securities analyst Jason Kupferberg maintains Paysafe (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSFE#NYSE">PSFE</a>) with a Underperform and lowers the price target from $18 to $16.

PSFE

B of A Securities Maintains Underperform on Paysafe, Lowers Price Target to $16

On March 7, 2025, Volcon ePowersports ("Volcon" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLCN#NASDAQ">VLCN</a>), a provider of electric vehicles today announced that its Board of Directors has authorized a share repurchase program, allowing for the repurchase of up to $2 million of the Company's common stock through March 7, 2026.

Buybacks

VLCN

Volcon Announces Board Authorization Of $2M Share Repurchase Program

B of A Securities analyst Joshua Shanker maintains Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) with a Buy and lowers the price target from $333 to $318.

B of A Securities Maintains Buy on Progressive, Lowers Price Target to $318

BloomZ Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) ("BloomZ" or the "Company"), a Japanese audio production, VTuber, entertainment, and voice actor management company, announced the appointment of Ryoshin Nakade as the co-Chief Executive Officer and co-Chairman of the Board, effective March 7, 2025. In this role, Mr. Nakade will serve alongside co-Chief Executive Officer Kazusa Aranami to lead the Company into its next phase of growth.

Management

BLMZ

BloomZ Appoints Ryoshin Nakade As Co-Chief Executive Officer And Co-Chairman Of The Board

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP
Clears the way to finalize Phase 3 protocol and recruit sites for U.S.
Phase 3 substantially funded by $17.0 million CPRIT grant and $8.5 million Company match
Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the results of its Type C meeting with the U.S. Food and Drug Administration ("FDA") regarding the protocol for the planned registrational Phase 3 study of eRapa in familial adenomatous polyposis ("FAP").
The Type C meeting followed a productive End of Phase 2 meeting with FDA and the publication of Phase 2 data of eRapa in FAP at six months at Digestive Disease Week in May 2024 and 12 months data at InSight, Barcelona in June 2024. The Type C meeting included a discussion of the statistical plan, the safety database and, most importantly, a composite endpoint for the Phase 3 study. FDA representatives from both Gastroenterology and Oncology Divisions provided valuable input into the proposed program and the Company believes there is a clear path forward for initiation of the registrational Phase 3 study in FAP in the U.S. next quarter.
The planned registrational Phase 3 study of eRapa in FAP will be a double-blind placebo-controlled trial in 168 patients, randomized 2:1 drug / placebo. It is expected the study will be conducted in approximately 30 clinical sites across the US and Europe. The US component of the study will be conducted by LumaBridge, based in San Antonio, Texas and the European component will be conducted by Precision for Medicine LLC. The Phase 3 study is supported by a $17.0 million grant from the Cancer Prevention Research Institute of Texas ("CPRIT") and a Company match of $8.5 million which has already been paid, in full, into escrow.

BDRX

Biodexa Announces Outcome Of Type C Meeting With FDA Regarding The Phase 3 Program For eRapa In FAP; Clears The Way To Finalize Phase 3 Protocol And Recruit Sites For U.S.

B of A Securities analyst Tal Liani initiates coverage on SailPoint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>) with a Buy rating and announces Price Target of $27.5.

Initiation

SAIL

B of A Securities Initiates Coverage On SailPoint with Buy Rating, Announces Price Target of $27.5

D. Boral Capital analyst Jason Kolbert maintains Coya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COYA#NASDAQ">COYA</a>) with a Buy and maintains $15 price target.

COYA

D. Boral Capital Maintains Buy on Coya Therapeutics, Maintains $15 Price Target

LIXT

LIXTE Biotechnology Announces Pre-Clinical Data Published In BioXriv And International Journal Of Pharmaceutics Confirming LB-100's Conversion To Active Form Endothall, An Effective Cancer Treatment In Combination With Immunotherapy; Potential Biomarker Identified For LB-100 Response

B of A Securities analyst Tim Anderson initiates coverage on Aardvark Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AARD#NASDAQ">AARD</a>) with a Buy rating and announces Price Target of $22.

AARD

B of A Securities Initiates Coverage On Aardvark Therapeutics with Buy Rating, Announces Price Target of $22

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="936" height="556" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/10121108/image-1.jpeg" alt="" class="wp-image-7488" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/10121108/image-1.jpeg 936w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/10121108/image-1-300x178.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/10121108/image-1-768x456.jpeg 768w" sizes="(max-width: 936px) 100vw, 936px" /></figure>
<a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F5e970678-71d0-4cb6-9011-2f2ab5f7ceac_1024x608.png" target="_blank" rel="noreferrer noopener"></a>When companies withdraw guidance, you know uncertainty is high.
The word "uncertainty" gets thrown around a lot in discussions about the stock market.
And it's not surprising. There is&nbsp;<a href="https://www.tker.co/p/always-risks-uncertainty-in-stock-market">literally always</a>&nbsp;something to be uncertain about. In fact, uncertainty defines the risk stock market investors take as they bet on a future that isn't guaranteed. Uncertainty gives risk-tolerant investors the opportunity to buy stocks at a discount. Uncertainty is why the returns in the stock market tend to be relatively high.
But far too often, pundits will appear on TV or get quoted in a news article casually saying that "uncertainty is elevated" — when in fact uncertainty may be at normal levels. Because there is always uncertainty, and any implication that there can be periods with no uncertainty is ridiculous.
Of course, there are times when uncertainty explodes above typical levels. And they come with some very glaring signs.
When companies everywhere withdraw guidance &#x1f9d1;&#x1f3fb;&#x200d;&#x1f9af;&#x200D;&#x27a1;&#xFE0F;
Five years ago this week, the World Health Organization&nbsp;<a href="https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020">declared</a>&nbsp;that COVID-19 as a pandemic.
In the weeks prior, there had already been concerns about the seriousness of the outbreak. But it wasn't until mid-March that we began to see huge parts of the economy get shut down in the effort to contain the spread of the virus. And it would be months before we got a sense of what this unprecedented disruption would mean for the economy.
Businesses around the world were not prepared.
Most companies operate assuming a range of probable future outcomes. And for many publicly traded companies, the midpoint of that range is presented to investors in the form of quarterly and annual financial guidance. As the quarter and year proceeds, companies will sometimes raise guidance. Sometimes they'll lower guidance.
Things have to get really bad for companies to withdraw or suspend guidance.
That's exactly&nbsp;<a href="https://finance.yahoo.com/news/corporations-suspend-withdraw-earnings-guidance-analysts-strategists-blind-134417231.html">what a flood of companies did</a>&nbsp;in early 2020 as they had little to no visibility into what business would look like in the near term.
<a href="https://x.com/SamRo/status/1249814452649803777">According to BofA</a>, 71 S&amp;P 500 companies withdrew guidance from March 2 to April 7 that year.
Zooming out a bit, 173 Russell 3000 companies withdrew guidance during the first quarter,&nbsp;<a href="https://www.spglobal.com/content/dam/spglobal/mi/en/documents/general/QR-Brief-Cold-Turkey-Navigating-Guidance-Withdrawal-with-Supply-Chain_Data.pdf">according to S&amp;P Global</a>. The chart below shows how unusual that was.
<a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0c40d76f-4f39-4cd7-82cd-a980aae76630_1474x1142.png" target="_blank" rel="noreferrer noopener"></a>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="935" height="724" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/10121108/image-1-1.jpeg" alt="" class="wp-image-7489" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/10121108/image-1-1.jpeg 935w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/10121108/image-1-1-300x232.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/10121108/image-1-1-768x595.jpeg 768w" sizes="(max-width: 935px) 100vw, 935px" /></figure>
<a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0c40d76f-4f39-4cd7-82cd-a980aae76630_1474x1142.png" target="_blank" rel="noreferrer noopener"></a>
In Q1 2020, 173 Russell 3000 companies withdrew guidance. (Source:&nbsp;<a href="https://www.spglobal.com/content/dam/spglobal/mi/en/documents/general/QR-Brief-Cold-Turkey-Navigating-Guidance-Withdrawal-with-Supply-Chain_Data.pdf">S&amp;P Global</a>)
"The question for managers is: Do they know about future performance substantially more than investors do?" NYU Professor Baruch Lev&nbsp;<a href="https://finance.yahoo.com/news/wall-st-economists-analysts-guess-forecasts-morning-brief-102219423.html">told me at the time</a>. "My guess is that in most cases managers aren't now better informed than investors. We are all in the dark. In that case, guidance is futile."
It's one thing for a company to revise guidance lower. It's another much scarier thing for a company to admit they just don't know where things are headed.
That's real uncertainty.
This speaks to&nbsp;<a href="https://www.tker.co/i/42137695/the-most-destabilizing-risks-are-the-ones-people-arent-talking-about">TKer Stock Market Truth No. 8</a>: "The most destabilizing risks are the ones people aren't talking about."
Pandemic risk was effectively on no one's radar going into 2020. Companies didn't have plans for addressing it, and it wasn't priced into the market. It's why the S&amp;P 500 was able to rally to its then record high of 3,393 on February 19 before tumbling 35% to its low of 2,191 on March 23.
Tariffs: Bad, but it could be worse &#x1f52d;
Most informed folks agree raising tariffs is a <a href="https://www.tker.co/p/wall-street-agrees-tariffs-are-bad">net negative for the economy</a>, so an uptick in uncertainty is warranted.
And lot of companies have said that the effect of tariffs&nbsp;<a href="https://www.tker.co/i/156333109/tariffs-are-not-factored-into-earnings-guidance">haven't been factored into their earnings guidance</a>. Maybe we'll soon hear about companies revising their guidance lower.
But will companies start withdrawing guidance in droves? I'm not convinced they will.
The threat of tariffs has been out there&nbsp;<a href="https://www.tker.co/p/wall-street-agrees-tariffs-are-bad">for months</a>. And for months, many companies have&nbsp;<a href="https://www.tker.co/p/companies-react-to-tariffs">announced plans for addressing</a>&nbsp;new tariffs, including&nbsp;<a href="https://www.tker.co/p/sales-pull-forward-frontrunning-tariffs">stockpiling goods</a>&nbsp;ahead of tariffs and&nbsp;<a href="https://www.tker.co/p/companies-pass-on-costs-tariffs-to-end-consumer">raising prices</a>&nbsp;once tariffs are imposed.
It would've been much worse if President Trump had announced the imposition of tariffs with no warning.
To be clear, tariffs and global pandemics are two very different things. But both are similar in that they come with supply chain disruptions and higher costs of goods. And the more advanced notice companies have, the more time they have to prepare operations for the risk.
This is not to say we won't experience market volatility in the coming months. The S&amp;P 500 experiences an&nbsp;<a href="https://www.tker.co/p/stock-market-down-days-drawdowns-down-years-normal">average annual max drawdown of 14%</a>.
But I think we should <a href="https://www.tker.co/p/dangerous-to-underestimate-corporate-america">be careful about underestimating</a> the resilience of Corporate America, especially when they've had time to prepare for what may be coming.

Equities

Market Summary

Broad U.S. Equity ETFs

Opinion

ETFs

When uncertainty becomes unambiguously high

INSE

Inspired Entertainment iGaming Content To Launch Through Rush Street Interactive' RushBet Platform In Mexico, Colombia and Peru And BetRivers Platform In Delaware

PMNT

Perfect Moment Says NYSE American Accepted Co. Plan To Regain Compliance

WIIM

SNES

SenesTech shares are trading lower after the company announced the exercise of warrants and will issue 1.498,872 shares of common stock.

Decent Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXST#NASDAQ">DXST</a>) reported quarterly earnings of $0.14 per share. This is a 16.67 percent increase over earnings of $0.12 per share from the same period last year. The company reported $11.54 million in sales this quarter. This is a 22.18 percent increase over sales of $9.45 million the same period last year.

Earnings

DXST

Decent Holding FY EPS $0.14 Up From $0.12 YoY, Sales $11.54M Up From $9.45M YoY

Press Releases

Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference

Health Care

Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference

Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors

Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer

Comments

Monte Rosa Therapeutics

Noticias

Últimas noticias sobre Monte Rosa Therapeutics (NASDAQ:GLUE) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL